Elutia Inc. (ELUT)
Automate Your Wheel Strategy on ELUT
With Tiblio's Option Bot, you can configure your own wheel strategy including ELUT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ELUT
- Rev/Share 0.614
- Book/Share -0.9441
- PB -1.8324
- Debt/Equity -0.8073
- CurrentRatio 0.8146
- ROIC -6.5218
- MktCap 71130095.0
- FreeCF/Share -0.7576
- PFCF -2.4315
- PE -1.6748
- Debt/Assets 0.7489
- DivYield 0
- ROE 0.8519
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Elutia to Report First Quarter 2025 Financial Results on Thursday, May 8, 2025
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
SILVER SPRING, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its first quarter 2025 financial results after market close on Thursday, May 8, 2025. Members of the Company's management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day.
Read More
Elutia Initiates EluPro™ Registry Study Designed to Generate Evidence Supporting the Use of EluPro in Real-World Clinical Practice
Published: April 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
— Integration of clinical and patient-reported outcomes expected to further differentiate EluPro's utility in cardiac implantable electronic device (CIED) procedures — SILVER SPRING, Md., April 21, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced the initiation of an EluPro™ clinical study designed to collect patient outcome data in real-world clinical practice.
Read More
Elutia to Participate in Upcoming Investor Conferences
Published: April 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
SILVER SPRING, Md., April 03, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, President and Chief Executive Officer, and Matt Ferguson, Chief Financial Officer, will participate in the following upcoming investor conferences:
Read More
About Elutia Inc. (ELUT)
- IPO Date 2020-10-08
- Website https://elutia.com
- Industry Biotechnology
- CEO Dr. C. Randal Mills Ph.D.
- Employees 51